Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC10A2 | Q12908 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30989920 | 0.98 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC10A2HTR2AANPEP | |
| Hydrochloric Acid SCHEMBL30989811 | 0.98 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC10A2HTR2AANPEP | |
| SCHEMBL13499160 | 0.80 | CA2 (0.41) | SLC6A2SLC6A4SLC10A2HTR2AANPEP | |
| SCHEMBL2906600 | 0.80 | CA2 (0.41) | SLC6A2SLC6A4SLC10A2HTR2AANPEP | |
| Hydrochloric Acid SCHEMBL1002826 | 0.79 | CA2 (0.42) | SLC10A2ANPEPCA2 | |
| SCHEMBL14275866 | 0.77 | ADRA1D (0.34) | SLC6A2SLC6A4SLC10A2ANPEPCA2 | |
| SCHEMBL12180971 | 0.75 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC10A2HTR2AGPR3 | |
| SCHEMBL21266523 | 0.75 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC10A2HTR2AGPR3 | |
| SCHEMBL21032138 | 0.75 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC10A2GPR3PLCG1 | |
| SCHEMBL19117718 | 0.75 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC10A2HTR2AGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | claimed |
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | SLC6A2 487/4885SLC6A4 646/4885SLC10A2 4110/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | SLC6A2 280/4885SLC6A4 267/4885SLC10A2 3987/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | SLC6A2 585/4885SLC6A4 853/4885SLC10A2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.